BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lièvre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepère C, Bachet JB, Portales F, Vaillant JN, Ychou M, Rougier P. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer 2009;9:347. [PMID: 19785749 DOI: 10.1186/1471-2407-9-347] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Abdelwahab S, Azmy A, Abdel-aziz H, Salim H, Mahmoud A. Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC). J Cancer Res Clin Oncol 2012;138:1487-92. [DOI: 10.1007/s00432-012-1229-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
2 Lou E, Turner S, Sumrall A, Reardon DA, Desjardins A, Peters KB, Sampson JH, Friedman HS, Vredenburgh JJ. Bevacizumab-Induced Reversible Posterior Leukoencephalopathy Syndrome and Successful Retreatment in a Patient With Glioblastoma. JCO 2011;29:e739-42. [DOI: 10.1200/jco.2011.36.1865] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
3 Köstek O, Hacıoğlu MB, Sakin A, Demir T, Sarı M, Ozkul O, Araz M, Doğan AF, Demircan NC, Uzunoğlu S, Çiçin İ, Erdoğan B. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer? Cancer Chemother Pharmacol 2019;83:115-22. [PMID: 30374523 DOI: 10.1007/s00280-018-3713-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
4 Conley BA, Staudt L, Takebe N, Wheeler DA, Wang L, Cardenas MF, Korchina V, Zenklusen JC, McShane LM, Tricoli JV, Williams PM, Lubensky I, O'Sullivan-Coyne G, Kohn E, Little RF, White J, Malik S, Harris LN, Mann B, Weil C, Tarnuzzer R, Karlovich C, Rodgers B, Shankar L, Jacobs PM, Nolan T, Berryman SM, Gastier-Foster J, Bowen J, Leraas K, Shen H, Laird PW, Esteller M, Miller V, Johnson A, Edmondson EF, Giordano TJ, Kim B, Ivy SP. The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. J Natl Cancer Inst 2021;113:27-37. [PMID: 32339229 DOI: 10.1093/jnci/djaa061] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
5 Toyama Y, Ushigome T, Watanabe K, Kitamura H, Onda S, Saito R, Yoshida S, Kawahara H, Yanagisawa S, Yanaga K. Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report. World J Surg Oncol 2012;10:129. [PMID: 22747970 DOI: 10.1186/1477-7819-10-129] [Reference Citation Analysis]
6 Elmalik HH, ElAzzazy S, Salem KS, Bujassoum S. A Grave Outcome of Posterior Reversible Encephalopathy Syndrome in a Patient Receiving Avastin (Bevacizumab) for Metastatic High-Grade Serous Ovarian Cancer. Case Rep Oncol 2015;8:290-4. [PMID: 26351436 DOI: 10.1159/000435805] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
7 Prenen H, Vecchione L, Van Cutsem E. Role of targeted agents in metastatic colorectal cancer. Targ Oncol 2013;8:83-96. [DOI: 10.1007/s11523-013-0281-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
8 Ghiringhelli F, Vincent J, Guiu B, Chauffert B, Ladoire S. Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies. Invest New Drugs. 2012;30:758-764. [PMID: 21057973 DOI: 10.1007/s10637-010-9575-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
9 Wu Q, Shi Y, Chen L, Xiao X, Dai G. Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer. Onco Targets Ther. 2013;6:485-490. [PMID: 23671391 DOI: 10.2147/OTT.S41449] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
10 Fernández-Montes A, Grávalos C, Pericay C, Safont MJ, Benavides M, Élez E, García-Alfonso P, García-Paredes B, Carrato A, Aranda E. Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. Clin Colorectal Cancer 2020;19:165-77. [PMID: 32507561 DOI: 10.1016/j.clcc.2020.04.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Cheng MR, Li Q, Wan T, He B, Han J, Chen HX, Yang FX, Wang W, Xu HZ, Ye T, Zha BB. Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects. World J Gastroenterol 2012; 18(42): 6076-6087 [PMID: 23155336 DOI: 10.3748/wjg.v18.i42.6076] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
12 Abajo A, Bitarte N, Zarate R, Boni V, Lopez I, Gonzalez-Huarriz M, Rodriguez J, Bandres E, Garcia-Foncillas J. Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array. World J Gastroenterol 2012; 18(7): 637-645 [PMID: 22363134 DOI: 10.3748/wjg.v18.i7.637] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
13 Beretta GD, Petrelli F, Stinco S, Cabiddu M, Ghilardi M, Squadroni M, Borgonovo K, Barni S. FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials. Med Oncol. 2013;30:486. [PMID: 23400961 DOI: 10.1007/s12032-013-0486-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
14 Abajo A, Boni V, Lopez I, Gonzalez-Huarriz M, Bitarte N, Rodriguez J, Zarate R, Bandres E, Garcia-Foncillas J. Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients. Br J Cancer 2012;107:287-90. [PMID: 22699823 DOI: 10.1038/bjc.2012.242] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
15 Yigit O, Kulak Kayikci ME, Temucin CM, Sarac S, Erman M, Belgin E. Electrophysiologic evaluation of facial nerve functions after oxaliplatin treatment. Cancer Chemother Pharmacol 2019;84:513-20. [PMID: 30997533 DOI: 10.1007/s00280-019-03841-2] [Reference Citation Analysis]
16 Dost Gunay FS, Kırmızı BA, Ensari A, İcli F, Akbulut H. Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer. Clin Colorectal Cancer 2019;18:e244-50. [PMID: 30670344 DOI: 10.1016/j.clcc.2018.12.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
17 Park LC, Lee HS, Shin SH, Park SJ, Park MI, Oh SY, Kwon HC, Baek JH, Choi YJ, Kang MJ, Kim YS. Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer. World J Gastroenterol 2012; 18(10): 1104-1109 [PMID: 22416186 DOI: 10.3748/wjg.v18.i10.1104] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
18 Temraz S, Mukherji D, Alameddine R, Shamseddine A. Methods of overcoming treatment resistance in colorectal cancer. Crit Rev Oncol Hematol 2014;89:217-30. [PMID: 24075059 DOI: 10.1016/j.critrevonc.2013.08.015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
19 Arnold D, Prager GW, Quintela A, Stein A, Moreno Vera S, Mounedji N, Taieb J. Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. Ann Oncol 2018;29:835-56. [PMID: 29452346 DOI: 10.1093/annonc/mdy038] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
20 Muglia C, Mercer N, Toscano MA, Schattner M, Pozner R, Cerliani JP, Gobbi RP, Rabinovich GA, Docena GH. The glycan-binding protein galectin-1 controls survival of epithelial cells along the crypt-villus axis of small intestine. Cell Death Dis 2011;2:e163. [PMID: 21614093 DOI: 10.1038/cddis.2011.44] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
21 Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, François E, Ychou M, Goldwasser F, Bouché O. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Clin Colorectal Cancer. 2012;11:38-44. [PMID: 21803002 DOI: 10.1016/j.clcc.2011.05.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
22 Abajo A, Rodriguez J, Bitarte N, Zarate R, Boni V, Ponz M, Chopitea A, Bandres E, Garcia-Foncillas J. Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients. Br J Cancer 2010;103:1529-35. [PMID: 20940716 DOI: 10.1038/sj.bjc.6605908] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
23 Chang Y, Mbeo G, Littman SJ. Reversible posterior leukoencephalopathy syndrome associated with concurrent bevacizumab, gemcitabine, and oxaliplatin for cholangiocarcinoma. J Gastrointest Cancer 2012;43:505-7. [PMID: 21556724 DOI: 10.1007/s12029-011-9279-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
24 Cavia-Saiz M, Muñiz P, De Santiago R, Herreros-Villanueva M, Garcia-Giron C, Lopez AS, Coma-Del Corral MJ. Changes in the levels of thioredoxin and indoleamine-2,3-dioxygenase activity in plasma of patients with colorectal cancer treated with chemotherapy. Biochem Cell Biol 2012;90:173-8. [PMID: 22257103 DOI: 10.1139/o11-077] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
25 Jary M, Borg C, Bouché O, Kim S, André T, Bennouna J. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?]. Bull Cancer 2015;102:758-71. [PMID: 26232849 DOI: 10.1016/j.bulcan.2015.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
26 Mao L, Li Y, Zhao J, Li Q, Yang B, Wang Y, Zhu Z, Sun H, Zhai Z. Transforming growth factor-β1 contributes to oxaliplatin resistance in colorectal cancer via epithelial to mesenchymal transition. Oncol Lett 2017;14:647-54. [PMID: 28693217 DOI: 10.3892/ol.2017.6209] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
27 Yamaguchi K, Taniguchi H, Komori A, Narita Y, Nitta S, Nomura M, Kadowaki S, Takahari D, Ura T, Andoh M, Muro K, Mori K, Igarashi Y. A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer. BMC Cancer 2015;15:601. [PMID: 26311588 DOI: 10.1186/s12885-015-1606-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
28 Geva R, Vecchione L, Tejpar S, Piessevaux H, Van Cutsem E, Prenen H. Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer. Onco Targets Ther. 2013;6:53-58. [PMID: 23378775 DOI: 10.2147/ott.s41383] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
29 Min ST, Roohullah A, Tognela A, Jalali A, Lee M, Wong R, Shapiro J, Burge M, Yip D, Nott L, Zimet A, Lee B, Dean A, Steel S, Wong HL, Gibbs P, Lim SH. Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an australian population. Asia Pac J Clin Oncol 2021. [PMID: 33870631 DOI: 10.1111/ajco.13553] [Reference Citation Analysis]
30 Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, Kerbel RS. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 2011;13:40-8. [PMID: 21245939 DOI: 10.1593/neo.101174] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
31 Sogabe S, Komatsu Y, Yuki S, Kusumi T, Hatanaka K, Nakamura M, Kato T, Miyagishima T, Hosokawa A, Iwanaga I, Sakata Y, Asaka M. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study. Jpn J Clin Oncol 2011;41:490-7. [PMID: 21303790 DOI: 10.1093/jjco/hyr008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
32 Guan ZZ, Xu JM, Luo RC, Feng FY, Wang LW, Shen L, Yu SY, Ba Y, Liang J, Wang D, Qin SK, Wang JJ, He J, Qi C, Xu RH. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer 2011;30:682-9. [PMID: 21959045 DOI: 10.5732/cjc.011.10188] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 8.6] [Reference Citation Analysis]
33 Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken J, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'hoore A, Diaz-rubio E, Douillard J, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne C, Labianca R, Laurent-puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen W, Papamichael D, Pentheroudakis G, Pfeiffer P, Price T, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll H, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology 2016;27:1386-422. [DOI: 10.1093/annonc/mdw235] [Cited by in Crossref: 1387] [Cited by in F6Publishing: 1268] [Article Influence: 277.4] [Reference Citation Analysis]
34 MacConaill LE, Garcia E, Shivdasani P, Ducar M, Adusumilli R, Breneiser M, Byrne M, Chung L, Conneely J, Crosby L, Garraway LA, Gong X, Hahn WC, Hatton C, Kantoff PW, Kluk M, Kuo F, Jia Y, Joshi R, Longtine J, Manning A, Palescandolo E, Sharaf N, Sholl L, van Hummelen P, Wade J, Wollinson BM, Zepf D, Rollins BJ, Lindeman NI. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn 2014;16:660-72. [PMID: 25157968 DOI: 10.1016/j.jmoldx.2014.06.004] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 7.0] [Reference Citation Analysis]
35 Zoratto F, Rossi L, Zullo A, Papa A, Zaccarelli E, Tomao L, Giordani E, Colonna M, Baiano G, Tomao S. Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. Onco Targets Ther 2012;5:199-211. [PMID: 23055745 DOI: 10.2147/OTT.S30581] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Dirican A, Kucukzeybek Y, Alacacioglu A, Varol U, Aksun S, Bayoglu IV, Demir L, Coban E, Sutcu R, Tarhan MO. Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer. Med Oncol 2014;31. [DOI: 10.1007/s12032-014-0905-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]